Dual-masked PRO-XTEN design aims to limit systemic toxicity by activating VIR-5500 via tumor-associated protease cleavage within the microenvironment while retaining PSMA-targeted T-cell redirection.

Testosterone replacement therapy may not increase prostate cancer recurrence risk, but evidence remains inconclusive, necessitating individualized treatment plans. Bipolar androgen therapy (BAT) ...

High-powered holmium and thulium laser platforms are expanding ureteroscopic options for complex patients, including those on anticoagulation, while emerging technologies such as Break Wave ...

177Lu-PSMA-617 is now approved for PSMA-positive mCRPC patients post-ARPI therapy, delaying taxane-based chemotherapy. The phase 3 PSMAfore trial showed a 59% reduction in radiographic progression or ...

“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care ...

Pearlman and Rodriguez explore the persistent disconnect between medical treatment and quality-of-life conversations, particularly when it comes to sexual health. In this episode of The UroOnc Minute, ...

In this episode, Amy Pearlman, MD, sits down with Alan J. Wein, MD, PhD (hon), FACS, to discuss how the field of urology has evolved and how clinicians can thoughtfully evolve alongside it. Jonathan ...

The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...

"We have over 30 years of safety data, and no adverse events in over 30 years," says Heather Florio. In this interview, Heather Florio and Stephen J. Walker, PhD, discuss the use of aloe vera in ...

Novel therapies are promising but face questions about patient selection and efficacy. Erectile dysfunction is a common concern among aging males. Not only does ED affect quality of life, but it is ...

Researchers at the Mayo Clinic report that they have developed a legitimate penile traction therapy device for men with Peyronie’s disease that may work when used for just 30 to 90 minutes daily.

Although low, men experienced a higher risk for erectile dysfunction and hypogonadism after being prescribed semaglutide for weight loss; however, further questions remain. Non-diabetic men treated ...